Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy

Clinical Lymphoma and Myeloma

Volumn 8, Issue 6, 2008, Pages 356-358

  Johnston, Anna ^a   Salles, Gilles ^a   Espinouse, Daniel ^a   Felman, Pascale ^a   André, Patrice ^a   Berger, Françoise ^a   Coiffier, Bertrand ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Follicular lymphoma; Secondary disease; Viral hemophagocytic syndrome

Indexed keywords

ANTIBIOTIC AGENT; BILIRUBIN; CD19 ANTIGEN; CD20 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMOGLOBIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BILIRUBIN BLOOD LEVEL; BLOOD EXAMINATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CD4+ T LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE SEQUENCE; DRUG MEGADOSE; EPSTEIN BARR VIRUS; ERYTHROPHAGOCYTOSIS; FEMALE; FEVER; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HEMOGLOBIN BLOOD LEVEL; HEPATOSPLENOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; HYPERFERRITINEMIA; HYPERTRIGLYCERIDEMIA; HYPOFIBRINOGENEMIA; IMMUNOGLOBULIN DEFICIENCY; IMMUNOHISTOCHEMISTRY; JAUNDICE; LEUKOCYTE COUNT; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; NEPHELOMETRY; NEUTROPHIL COUNT; PANCYTOPENIA; PARTIAL THROMBOPLASTIN TIME; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; TREATMENT DURATION; VIRUS REACTIVATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; VIROLOGY; VIRUS ACTIVATION; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA, FOLLICULAR; LYMPHOPROLIFERATIVE DISORDERS; PREDNISONE; VINCRISTINE; VIRUS ACTIVATION;

EID: 59649098583     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.052     Document Type: Article

References (13)

1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757-68.
2. Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003; 163:1997-2004.
3. Shimoyama Y Oyama T, Asano N, et al. Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review. J Clin Exp Hematop 2006; 46:1-4.
4. Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002; 26:630-6.
5. Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122:139-45.
6. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33.
7. Lim SH, Zhang Y, Wang Z, et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 2005; 35:207-8.
8. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymph 2007; 48:1307-12.
9. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99:1486-8.
10. Rey J, Belmecheri N, Bouayed N, et al. JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab. Haematologica 2007; 92:e101.
11. Kim IJ, Flano E, Woodland DL, et al. Antibody-mediated control of persistent gamma-herpesvirus infection. J Immunol 2002; 168:3958-64.
12. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007; 86:599-607.
13. Nehring AK, Dua U, Mollee P, et al. Epstein-Barr virus T-cell immunity despite rituximab. Br J Haematol 2007; 136:628-32.